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Abstract 
Background. Human parvovirus B19 infection generally displays a self-limiting course 
followed by viral clearance; although, in some cases, persistent infection may occur. Few 
cases of severe pulmonary disease following primary infection in both immunocompetent 
and immunocompromised patients were reported.  
Objectives. To investigate the prevalence and clinical impact of parvovirus B19 in the 
lower respiratory tract. 
Study design. The prevalence of parvovirus B19-DNA was evaluated by Real-Time PCR 
in 264 bronchoalveolar lavages (BAL) from 189 adult patients over a full-year period and 
related to demographic characteristics, underlying pathologies, immune status, admission 
to intensive care unit, mortality within 28 days, and discharge diagnosis. 
Results. Parvovirus B19-DNA was detected in 7/189 (3.7%) patients, without significant 
association to demographic characteristics, immune status, transplant versus non-
transplant status, admission to intensive care unit, presence of haematological conditions. 
In two lung transplant recipients surveillance specimens were positive to B19. Four of the 
remaining five patients presented respiratory insufficiency. A significant association to 
mortality was found, as 3/7 (42.9%) positive-patients died within 28 days. No patient 
presented serological evidence of recent or acute infection and viremia.  
Conclusions. Parvovirus B19 may be detected at low frequency in BAL specimens from 
patients with different  pathological background. This finding could be due to chronic 
infection with virus persistence in the lower respiratory tract, also in the absence of 
symptoms unequivocally attributable to B19. The high rate of mortality warrants the need 
for further studies to evaluate the opportunity to consider parvovirus B19 in the diagnostic 
work-up of lower respiratory tract infections.   
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Background. 
Human parvovirus B19 is a world-wide distributed single-stranded DNA virus usually 
infecting rapidly dividing cell lines, such as bone marrow erythroid progenitor cells.1 Most 
persons are infected by 15 years of age and about 80% of the population is seropositive 
by the age of 50 years. Infection is most common in late winter or early spring2 and occurs 
through exposure to infected respiratory droplets or blood products or vertically from 
mother to fetus. Most persons with B19 infection are asymptomatic or present mild, 
aspecific, cold-like symptoms. Other clinical conditions associated to parvovirus B19 
infection include erythema infectiosum, arthropathy, and hydrops fetalis in 
immunocompetent individuals; hematologic diseases, including aplastic crisis, chronic red 
cell aplasia, and idiopathic thrombocytopenic purpura, in immunocompromised patients. A 
link to parvovirus B19 infection has been hypothesized for various skin eruptions, 
neurologic diseases, rheumatologic diseases, vasculitic and myocarditic syndromes, and 
autoimmune hepatitis.3,4 Few cases of severe pulmonary disease in both 
immunocompetent and immunocompromised patients have been reported in literature;5-13 
however, at our knowledge, no study has systematically investigated the presence of 
parvovirus B19 in lower respiratory tract specimens.  
Objectives.  
The aim of this study was to evaluate the prevalence and clinical impact of parvovirus B19 
in bronchoalveolar lavage (BAL) specimens from hospitalized adult patients. 
Study design. 
All the 264 consecutive BAL samples collected over a period of 12 months at the Virology 
Unit of the Azienda Ospedaliero-Universitaria San Giovanni Battista in Turin and obtained 
from 189 patients (men/women, 121/78; mean age ± standard deviation, 57.8 ± 15.9 
years; range, 16-84) were studied. Multiple BAL procedures (mean, 3.2 ; range, 2-6) were 
performed on 30 patients. Samples from the same patient that were collected less than 2 
weeks apart were excluded; each sample and episode were evaluated independently. 
Bronchoalveolar lavage procedure was performed for investigating the cause of 
unexplained fever and/or respiratory symtpoms (including dyspnea, cough, hemoptysis) 
and/or new infiltrates on chest X-ray or in the absence of the above mentioned conditions 
for cheking up a previous positivity or as routine follow-up in lung transplant recipients at 
month 1 post-transplantation and subsequently at three-month intervals. In lung transplant 
recipients histopathological evaluation (periodic acid-Schiff, Masson‟s trichrome, and 
hematoxylin and eosin stains) on transbronchial lung biopsy was routinely performed. The 
BAL procedure was carried out as previously described14 and samples were thawed and 
liquefied with 1:1 N-acetylcisteine. Based on the clinical chart review, the following 
features were recorded: demographic characteristics; microbiological/virological (including 
a molecular panel able to detect 16 respiratory viruses, [i.e. human cytomegalovirus, 
human herpesvirus-6 and -7, Epstein-Barr virus, herpes simplex virus, human 
enteroviruses, human rhinoviruses, human bocavirus, human coronaviruses, influenza A 
and B viruses, parainfluenza viruses 1-3, respiratory syncytial virus, adenoviruses], as 
previously described)15 results on BAL specimen; underlying pathologies: in particular, 
transplantation, haematological conditions, immune status (immunosuppression due to 
anti-rejection treatment in transplant recipients, chemotherapy, HIV infection or long-term 
use of corticosteroids); admission to intensive care unit; mortality within 28 days from 
admission and/or sampling; year period of BAL sampling; and discharge diagnosis (made 
according to the International Classification of Diseases - Italian version 2002, based on 
the 9th revision Clinical Modification [ICD9CM], codes 480.XX-486.XX for pneumonia; 
460.XX-466.XX for acute respiratory insufficiency or other acute respiratory conditions; 
490.XX-519.XX for other pneumopathies; 491.21 for acute exacerbations of chronic 
obstructive pulmonary disease; 996.8 for transplant complications; 33.22 for 
bronchoscopy).   
Nucleid acid extraction was performed using the automated NucliSens easyMAG platform 
system (bioMeriéux, Marcy l‟Etoile, France), according to the manufacturer‟s instruction. 
Real time PCR assays were performed with the 7300 Real-Time PCR System (Applied 
Biosystems, Monza, Italy), by using TaqMan platform. Primers for parvovirus B19 DNA 
detection were designed within the VP1 and VP2 genes (accession number AY768535; 
primer F 5‟-ACATGCACACCTATTTTCCCAATAA-3‟, primer R 5‟-
TGTTCCATACAGAACCCACCATT-3‟; probe (TAMRA) 5‟-
AGCAATATACAGATCAAATTGAGCGCCCCC-3‟) using the Primer Express 3.0 Software 
(Applied Biosystems). The assay was carried out in 25 μl volume containing 5 μl of 
extracted specimen or plasmid dilution, 1× Master Mix (Platinum qPCR supermix – UDG 
with ROX, Invitrogen), 250 nM of each primer, 125 nM of probe. Uracil-DNA glycosylase 
was used to eliminate PCR „carry over‟ contaminations from previous PCR reactions.16 
The PCR cycling protocol was as follows: 50 °C for 2 min., initial denaturation step at 95°C 
for 10 min., followed by 45 cycles at 95°C for 15 sec. (denaturation) and 60°C for 1 min. 
(annealing and extension). Standard curves for the quantification of DNA were 
constructing by plotting the threshold cycle against the logarithm of serial 10-fold dilutions 
of the corresponding plasmid. Amplifications data were analyzed by the Sequence 
Detection System software (Applied Biosystem). Specimens were subjected to 
simultaneous TaqMan PCR detection of the housekeeping gene human Glycerin-
aldehyde-3-phosphate-dehydrogenase (GAPDH) as internal control, as previously 
described.17 Results were considered acceptable only in the presence of GAPDH with a 
threshold cycle (Ct) lower than 39. The assay had a detection limit of 10 copies/reaction, 
thus giving, based on the analytic procedure, a value of 125 genome equivalents (GEq)/ml 
of BAL. Dynamic range of Real Time PCR for Parvovirus B19 is shown in Figure 1. A 
“nucleotide-nucleotide blast” search for short nucleotide sequences performed at the 
National Centre of Biotechnology Information and the National Library of Medicine web site 
(available at: http://www.ncbi.nlm.nih.gov) confirmed that the primers used should not 
amplify other viruses pathogenic to humans. As a confirmatory test, a nested PCR that 
amplifies the VP1 region of Parvovirus B19 was also performed, as previously described.18 
Serology for parvovirus B19 was obtained from clinical charts or, in the available serum 
samples, was measured by commercial enzyme immunoassay (NovaLisa Parvovirus B19 
IgM and IgG, NovaTec Immundiagnostica, Dietzenbach, Germany).  
For descriptive statistics, raw data, percentages, mean and median were used. For 
statistical analysis, chi square test and Student‟s t test were used, as appropriate. A p 
value <0.05 was considered statistically significant. 
Results. 
Overall, parvovirus B19-DNA was detected in 7/264 (2.6%) specimens from 7/189 (3.7%) 
patients by Real Time PCR assay and confirmed by the nested PCR. Main features of 
patients with and without parvovirus B19  in BAL samples are reported in Table 1. The 
prevalence of parvovirus B19 positivity did not significantly differ in relation to demographic 
characteristics, immune status, transplant versus non-transplant status, admission to 
intensive care unit, presence of haematological conditions. In the two lung transplant 
recipients positive to B19 in surveillance BAL specimens, histopathological evaluation 
disclosed no finding suggestive of viral infection. Parvovirus B19 was significantly 
associated to mortality within 28 days, as 3/7 (42.9%) positive-patients required 
mechanical ventilation for respiratory insufficiency and died within 28 days. As regards 
seasonality, all the specimens positive to parvovirus B19 were collected in autumn or 
winter. Overall, serology for Parvovirus B19 was available for 106 patients: 77 (72.6%, 
including six of the seven positive to parvovirus B19 DNA on BAL specimen) with evidence 
of past infection (IgG positive, IgM negative) and none with evidence of acute or recent 
infection. Parvovirus B19 load ranged from 125 to 12943 GEq/ml BAL (median, 125) and 
did not significantly differ in relation to the above mentioned patient characteristics. Main 
features of parvovirus B19-positive patients are reported in Table 2.  Real Time PCR 
assay for parvovirus B19 resulted negative in all the available six serum specimens from 
the patients positive on BAL samples.   
Discussion. 
Parvovirus B19 is a common cause of infection worldwide and definitive diagnosis is made 
by the detection of IgM or viral DNA in serum samples, as well as B19-DNA may be 
detectable in respiratory secretions. Generally, B19 infection of immunocompetent 
individuals displays a self-limiting course followed by clearance of the virus from the host; 
although, in some cases, persistent infection may occur despite the presence of IgG 
antibodies. Beside blood and bone marrow, the persistence of parvovirus B19-DNA has 
been shown in skin, synovial, tonsils, liver, myocardial tissue, and kidney.19-25 Although 
parvovirus B19 infection and persistence have been associated with a wide range of 
diseases, the finding of viral DNA in different tissue specimens argued against its possible 
pathogenic role in some clinical contexts,22,24 suggesting that the detection of B19-DNA is 
not sufficient to postulate a relationship between the virus and specific diseases. In the 
present study we investigated the presence and clinical impact of parvovirus B19 in BAL 
specimens. Few reports on parvovirus B19-associated pneumonia in 
immunocompromised and immunocompetent patients as a result of primary infection have 
been described in literature, while no study has investigated the presence of parvovirus 
B19-DNA in lower respiratory tract specimens from a large group of hospitalized adult 
patients. Based on our results, parvovirus B19-DNA was found in a small percentage of 
patients with different pathological background, without evidencing any significant 
prevalence in a specific subgroup of patients. As regards the potential relationship with a 
particular clinical pattern, although five of the seven positive patients presented an acute 
respiratory condition, in the two lung transplant recipients B19-DNA was found also in 
surveillance BAL. This seems to argue against a possible pathogenic role of parvovirus 
B19 and the virus could represent an innocent bystander, the replication of which has 
been favoured by the impaired pulmonary background. The chronicity of parvovirus B19 
infection in cryptic sites, in the absence of viremia, because of delayed (or no) clearance 
from these areas has been suggested for the cerebrospinal fluid. This has been evidenced 
because cerebrospinal fluid is routinely taken as part of routine investigation in new cases 
of leukemia, the pathogenesis of which has been hypothesized to be related to parvovirus 
B19, and is supported by the fact that B19 is known to cause encephalitis.26  Similarly, 
based on our results, it is likely that another cryptic site of viral persistence is represented 
by the lower respiratory tract. Moreover, it is to note that viral load was moderate-low in 
both symptomatic and surveillance cases and that all the specimens, but one, presented at 
least a coinfection with another virus, mainly herpesviruses or rhinovirus. However, it may 
be likely that also herpesvirus DNA finding is attributable to latency in lung, as previously 
described.17 On the other hand, the presence of respiratory insufficiency in four of seven 
patients with B19 positivity in BAL specimen and frequent association with mortality within 
28 days (42.9% of the cases) suggests the need for further investigation of the presence of 
parvovirus B19 in BAL and lung biopsy specimens and of its role in different clinical 
settings, such as intensive care unit. 
In conclusion, our results suggest that parvovirus B19-DNA may be detected at low 
frequency in BAL specimens obtained from hospitalized adult patients with different  
pathological background. This finding could be due to chronic infection with virus 
persistence in the lower respiratory tract, also in the absence of symptoms unequivocally 
attributable to B19; nevertheless, the high rate of mortality in the few positive cases 
warrant the need for further studies to evaluate the opportunity to consider parvovirus B19 
in the diagnostic work-up of lower respiratory tract infections.   
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Table 1. Main features of patients with and without parvovirus B19 in 
bronchoalveolar lavage specimens. SOT, solid organ transplant; BMT, bone marrow 
transplant; ICU, intensive care unit. 
 
 Total Parvovirus B19 
Characteristics N (%) N + (%) N – (%) P-value 
Patient  
 Total 
      Male 
      Female 
 Mean age 
 
189 
    121 (64.0%) 
    68 (36.0%) 
57.8 ± 15.9 (16-84) 
 
7 (3.7%) 
     4 (57.1%) 
     3 (42.9%) 
62.0 ± 14.9 (38-78) 
 
182 (96.25%) 
        117 (64.3%) 
         65 (35.7%) 
57.8 ± 16.2 (16-84) 
 
- 
NS 
 
NS 
Immune status 
 Competent 
 Compromised 
 
65 (34.4%) 
124 (65.6%) 
 
3 (42.9%) 
4 (57.1%) 
 
62 (34.1%) 
120 (65.9%) 
 
NS 
Transplant 
    SOT 
    BMT 
Non transplant 
63 
     54 
     9 
126  
2 (28.6.2%) 
       2 (3.7%; lung) 
       0  
5 (71.4%) 
61 (33.6%) 
           52 (96.3%) 
           9 (100%) 
121 (66.4%) 
 
NS 
Admission to ICU 24 (15.0%) 3 (12.5%) 21 (87.5%) NS 
Mortality within 28 days 21 (13.1%) 3 (14.3%) 18 (85.7%) <0.05 
Haematological condition 40 (21.2%) 2 (5.0%) 38 (95.0%) NS 
Seasonality  
 Spring + Summer 
 Autumn +  Winter  
264 specimens 
81 
183 
 
0 
7 (4.1%)  
 
81 (100%) 
139 (95.9%) 
 
NS 
 
Table 2. Main features of patients positive to parvovirus B19-DNA in 
bronchoalveolar lavage. GEq, genome equivalents. 
 
Sex/age Underlying condition Immune 
status 
Clinical 
diagnosis 
Mortality  Viral load 
(GEq/ml) 
Other pathogens 
F/59 Haematological 
malignancy  on 
chemotherapy 
Compromised Respiratory 
insufficiency 
No 705 Human herpesvirus-6, 
Human rhinovirus 
M/59 Haematological 
malignancy on  
chemotherapy 
Compromised Pneumonia, 
sepsis 
Yes (at 3 
days) 
<125 Epstein-Barr virus, 
bacteria 
F/78 Acute respiratory 
condition 
Competent Respiratory 
insufficiency 
Yes (at 26 
days) 
<125 No 
M/38 Lung transplantation Compromised Follow-up 
bronchoscopy 
No 370 Human cytomegalovirus 
M/60 Acute respiratory 
condition 
Competent Respiratory 
insufficiency 
Yes (at 1 
day) 
<125 Human rhinovirus 
M/78 Acute respiratory 
condition 
Competent Respiratory 
insufficiency 
No <125 Human herpesvirus-7, 
Human rhinovirus 
F/43 Lung transplantation Compromised Follow-up 
bronchoscopy 
No 12943 Human cytomegalovirus, 
Human herpesvirus-7 
 
Figure 1. Dynamic range of Real Time PCR for Parvovirus B19. Ct, threshold cycle; 
regression line and 95% confidence intervals for dilutions from 101 to 1010 copies/reaction 
are reported. 
 
